Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Reshma Kewalramani

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

AstraZeneca AZ

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Earnings climbed above expectations in the second quarter

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

CRISPR gene-editing in cancer patients is safe, according to new study

Patients had no side effects following CRISPR treatment

- PMLiVE

Vertex continues upward trajectory with French Orkambi deal

Comes on the heels of similar reimbursement deal in England

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Vertex scores FDA approval for CF triple therapy Trikafta

Decision comes only a few months after therapy was filed

- PMLiVE

Labour Party takes aim at pharma, calls attention to Orkambi row

Proposal to introduce compulsory licensing faces industry criticism

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links